© 2024 Cogora - All Rights Reserved

'); slot2 = googletag.defineSlot('/21804779673/hpe_live/mpu1', [[300, 600], [300, 250], [300, 1000]], 'div-gpt-ad-1560526566997-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot3 = googletag.defineSlot('/21804779673/hpe_live/mpu2', [300,250], 'div-gpt-ad-1560784220575-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot4 = googletag.defineSlot('/21804779673/hpe_live/mpu3', [300,250], 'div-gpt-ad-1560784251022-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot5 = googletag.defineSlot('/21804779673/hpe_live/mpu4', [300, 250], 'div-gpt-ad-1563274753432-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/slider', [1, 1], 'div-gpt-slider').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinleft', [146, 900], 'div-gpt-ad-1679485212314-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinright', [146, 900], 'div-gpt-ad-1679485314324-0').addService(googletag.pubads()); slot1 = googletag.defineSlot('/21804779673/hpe_live/leaderboard', [[970, 250], [728, 90]], 'div-gpt-ad-1579859448100-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/footer', [728, 90], 'div-gpt-ad-1563274691467-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/Overlay', [640, 480], 'div-gpt-ad-1642681358066-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/stickyfoot', [ [970, 250], [728, 90] ], 'dfp_stickyfooter').addService(googletag.pubads()); var targeturl="legislation-and-regulation"; console.log("DFP set url-hpe='"+targeturl+"'"); googletag.pubads().collapseEmptyDivs(); googletag.pubads().enableSingleRequest(); // googletag.pubads().disableInitialLoad(); // BDG 03.03.2021 googletag.pubads().enableLazyLoad({ fetchMarginPercent: 0, // When the slot enters the viewport. renderMarginPercent: 0, }); // START OF Google Ads Manager Code which is refreshing the ad once it is viewable // googletag.pubads().addEventListener('impressionViewable', function(event) { var slot = event.slot; if (slot.getTargeting(REFRESH_KEY).indexOf(REFRESH_VALUE) > -1) { setTimeout(function() { googletag.pubads().refresh([slot]); }, SECONDS_TO_WAIT_AFTER_VIEWABILITY * 1); } }); // END OF Google Ads Manager Code which is refreshing the ad once it is viewable // googletag.enableServices(); }); //--> jQuery(window).scroll(function() { checkStick(); }); var mbannerid = '#div-gpt-ad-1563273235586-0'; var mfooterid = '#footermobilebanner'; var dfooterid = '#div-gpt-ad-1563274691467-0'; // Desktop sticky check function checkStick() { var launched = false; if (jQuery(window).height() > 500) { if (!jQuery('#dfp_stickyfooter').hasClass("closed")) { if (jQuery('#dfp_stickyfooter > div').length) { if (!jQuery('#dfp_stickyfooter > div').hasClass("cog-mb-sticky")) { var width = jQuery('#dfp_stickyfooter > div > iframe').width(); var height = jQuery('#dfp_stickyfooter > div > iframe').height(); if (parseInt(width) > 0) { launched = true; jQuery('#dfp_stickyfooter').attr('style', 'height: '+(height+30)+'px;').addClass('opened'); jQuery('#dfp_stickyfooter').append(''); jQuery('#dfp_stickyfooter > div').addClass('cog-mb-sticky floating footer'); jQuery('#dfp_stickyfooter > div').attr('style', 'position:absolute; bottom:0;'); jQuery('#dfp_stickyfooter svg.close').on('click', function() { jQuery(this).parent().removeClass('opened').addClass('closed'); }); } } } } } if (!launched) { // Ad not ready yet window.setTimeout(checkStick, 250); } } jQuery(document).ready(function() {checkStick();});

This site is intended for health professionals only

Home > Legislation and regulation > EMA clarifies new pharmacovigilance legislation

Published on 25 May 2012

Share this story:

RELATED ARTICLES

EMA clarifies new pharmacovigilance legislation

teaser

The European Medicines Agency has published a set of questions and answers concerning the initial phases of the operation of the pharmacovigilance legislation.

The document, published today, clarifies some practical considerations that pharmaceutical companies will need to take into account before and after the legislation starts to apply in July this year.

It includes the agreed position of the European Union (EU) regulatory network, following discussions between the Agency, national regulatory authorities and the European Commission services.

The document includes answers to frequently asked questions on the following topics:

Good pharmacovigilance practice guidelines;
Pharmacovigilance system master files and summary of the pharmacovigilance system;
Risk management plans;
Post-authorisation safety studies;
Periodic safety update reports and EU reference date list;
Literature monitoring;
Product information and the black symbol;
Adverse-drug-reaction reporting and signal management;
Renewals.

The Agency will update the question-and-answer document on a regular basis.

European Medicines Agency

Most read

1

Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan

2

Oral vitamin A could become an alternative to isotretinoin for acne

3

Amino acids supplement reduces muscle wasting and improves gut function in critically ill

4

Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest

5

Launch of the new Hospital Pharmacy Europe Mobile App

Be in the know

Subscribe to Hospital Pharmacy Europe newsletter and magazine

Share this story:

RELATED ARTICLES

x